Heart Failure Reviews最新文献

Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art. 塞马鲁肽在心力衰竭和动脉粥样硬化性心血管疾病中的应用：最新进展。

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-31 DOI: 10.1007/s10741-025-10506-1

Nikolaos Theodorakis, Magdalini Kreouzi, Maria Nikolaou

{"title":"Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art.","authors":"Nikolaos Theodorakis, Magdalini Kreouzi, Maria Nikolaou","doi":"10.1007/s10741-025-10506-1","DOIUrl":"https://doi.org/10.1007/s10741-025-10506-1","url":null,"abstract":"Cardiovascular disease mortality rates, which had steadily declined over decades, are now plateauing or reversing due to the global rise in type 2 diabetes mellitus (T2DM) and obesity. These cardiometabolic conditions contribute significantly to atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease. Among emerging pharmacological treatments, glucagon-like peptide-1 receptor agonists, particularly semaglutide, have shown benefits beyond diabetes and obesity management, including cardioprotective and renoprotective effects. This state-of-the-art review comprehensively analyzes current evidence from clinical trials, identifies critical insights, and outlines research directions regarding semaglutide use in HF, ASCVD, and diabetic nephropathy. In ASCVD, semaglutide has demonstrated significant reductions in major adverse cardiovascular events, supported by findings from meta-analyses of trials in patients with T2DM and the SELECT trial for patients without T2DM. In a prespecified analysis of the SELECT trial, semaglutide demonstrated significant reductions in cardiovascular mortality and HF hospitalizations for patients with HF and ASCVD. In HF with preserved ejection fraction and mildly reduced ejection fraction, semaglutide improved symptoms, physical function, natriuretic peptide levels, echocardiographic parameters, and HF hospitalizations, as shown in the STEP-HFpEF program and a pooled analysis of trials. Furthermore, evidence from the FLOW trial underscores semaglutide's renal and cardiovascular benefits in diabetic nephropathy, irrespective of body mass index. While these findings suggest semaglutide's efficacy in cardiorenal diseases, gaps in evidence remain, including the need for event-driven trials in HF populations without ASCVD and irrespective of obesity. Future research should address these gaps, which could potentially update guideline recommendations.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The application of neighborhood area deprivation index to improve health equity across the spectrum of heart failure: a review.

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-29 DOI: 10.1007/s10741-025-10492-4

Tracy T Makuvire, Jose L Lopez, Zara Latif, Damla Mergen, Christy N Taylor, Ersilia M DeFilippis, Nasrien E Ibrahim

{"title":"The application of neighborhood area deprivation index to improve health equity across the spectrum of heart failure: a review.","authors":"Tracy T Makuvire, Jose L Lopez, Zara Latif, Damla Mergen, Christy N Taylor, Ersilia M DeFilippis, Nasrien E Ibrahim","doi":"10.1007/s10741-025-10492-4","DOIUrl":"https://doi.org/10.1007/s10741-025-10492-4","url":null,"abstract":"Neighborhood environments play a key role in the development of individual risk factors for heart failure (HF) and impact health outcomes across the spectrum of HF. The area deprivation index (ADI) is an important composite measure of neighborhood depravity that has been associated with poor cardiovascular outcomes. The objective of our review is to discuss how neighborhood deprivation, with an emphasis on ADI, influences the spectrum of HF among patients and to propose solutions for ADI applications to improve the implementation of equitable care across the HF spectrum. MEDLINE/Pubmed was systematically searched to identify observational studies published between 2016 and 2024, examining the impact of ADI on HF risk, management, and outcomes. The search involved crossing two sets of terms included in article titles and abstracts: (1) social deprivation, area deprivation index, and neighborhood deprivation; (2) cardiovascular disease risk, heart failure, heart failure medications, and heart failure outcomes. Additional references were identified through searching relevant author reference lists and review articles. Key findings suggest that (1) the prevalence of HF risk is increased in individuals residing in neighborhoods with higher ADI; (2) HF patients living in more deprived neighborhoods have increased odds of being hospitalized for HF; (3) after HF admission, the relationship between ADI and risk for readmissions varies by race; and (4) there is an excess 30-day mortality of HF associated with race and neighborhood deprivation. The ADI is an important value to consider in patients with HF, given its association with clinical outcomes. Therefore, we suggest practical ways to incorporate ADI into the management of patients with HF to improve equitable outcomes.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic venous insufficiency in heart failure: exploring a reciprocal influence on cardiovascular health.

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-29 DOI: 10.1007/s10741-025-10508-z

Vito A Damay, Ignatius Ivan, Victor Manuel Canata Benitez

{"title":"Chronic venous insufficiency in heart failure: exploring a reciprocal influence on cardiovascular health.","authors":"Vito A Damay, Ignatius Ivan, Victor Manuel Canata Benitez","doi":"10.1007/s10741-025-10508-z","DOIUrl":"https://doi.org/10.1007/s10741-025-10508-z","url":null,"abstract":"Chronic venous insufficiency (CVI) is a prevalent disorder, arising from venous valve incompetence and vein wall weakness, which impairs blood return and leads to venous stasis and hypertension in the lower extremities. This condition, affecting up to 40% of older adults, has been primarily considered a peripheral issue. However, growing evidence indicates its systemic impacts, notably its contribution to cardiovascular dysfunction and heart failure (HF). CVI exacerbates central venous pressure and cardiac preload, placing strain on the right heart and predisposing at-risk patients to HF. Moreover, a feedback loop exists where HF worsens CVI through increased venous stasis and fluid overload, highlighting a complex bidirectional relationship. Emerging research reveals that CVI-driven inflammation and endothelial dysfunction may accelerate adverse cardiac dysfunction. This review provides a comprehensive analysis of CVI's systemic effects, emphasizing the need for integrated cardiovascular and venous management strategies to address the reciprocal influences of CVI and HF. Such an approach could reduce disease progression and enhance outcomes for affected patients.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Worsening heart failure: progress, pitfalls, and perspectives.

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-28 DOI: 10.1007/s10741-025-10507-0

Cândida Fonseca, Rui Baptista, Fátima Franco, Brenda Moura, Joana Pimenta, Pedro Moraes Sarmento, José Silva Cardoso, Dulce Brito

引用次数: 0

Electronic health record nudges to optimize guideline-directed medical therapy for heart failure.

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-19 DOI: 10.1007/s10741-025-10503-4

Michael A Fuery, Katherine A Clark, Nikhil V Sikand, Sara R Tabtabai, Sounok Sen, F Perry Wilson, Nihar R Desai, Tariq Ahmad, Marc D Samsky

{"title":"Electronic health record nudges to optimize guideline-directed medical therapy for heart failure.","authors":"Michael A Fuery, Katherine A Clark, Nikhil V Sikand, Sara R Tabtabai, Sounok Sen, F Perry Wilson, Nihar R Desai, Tariq Ahmad, Marc D Samsky","doi":"10.1007/s10741-025-10503-4","DOIUrl":"https://doi.org/10.1007/s10741-025-10503-4","url":null,"abstract":"Electronic health record (EHR) alert nudges are emerging as a valuable tool for improving heart failure (HF) management, particularly by enhancing the use of guideline-directed medical therapy (GDMT). These nudges, integrated as clinical decision support (CDS) tools within EHR systems, provide real-time, evidence-based prompts that assist clinicians in making informed treatment decisions at critical moments in patient care. Studies have shown that targeted alerts can improve GDMT adherence and outcomes. Designing effective nudges requires aligning alert content, timing, and format with clinician workflows to reduce alert fatigue and enhance usability. Furthermore, involving clinicians in the design process helps ensure alerts are relevant, context-sensitive, and integrated smoothly into practice. EHR nudges present an innovative approach to bridging quality gaps in HF care by encouraging timely interventions and adherence to best practices, but their efficacy depends on thoughtful implementation. Future research is needed to refine alert strategies, optimize their impact on clinical outcomes, and explore their role across diverse healthcare settings, ultimately advancing the potential of EHR nudges to improve HF care quality.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart and brain interactions in heart failure: pathophysiological mechanisms and clinical perspectives.

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-18 DOI: 10.1007/s10741-025-10505-2

Sotiria Liori, Angelos Arfaras-Melainis, Vasiliki Bistola, John Parissis

{"title":"Heart and brain interactions in heart failure: pathophysiological mechanisms and clinical perspectives.","authors":"Sotiria Liori, Angelos Arfaras-Melainis, Vasiliki Bistola, John Parissis","doi":"10.1007/s10741-025-10505-2","DOIUrl":"https://doi.org/10.1007/s10741-025-10505-2","url":null,"abstract":"Heart failure (HF) is a complex and debilitating syndrome that affects millions of people worldwide. In addition to the syndrome-related functional limitations, such as exercise intolerance and dyspnea, patients frequently suffer from various comorbidities. Neuropsychiatric conditions, including autonomic dysfunction, cognitive impairment, and depression, are important albeit underrecognized comorbidities in HF. Autonomic dysfunction, which is expressed as sympathetic predominance and decreased parasympathetic tone, is a key contributor to HF progression. Depression and cognitive impairment are highly prevalent in HF patients, affecting adherence to medical treatment and increasing morbidity and mortality risk. Stress cardiomyopathy, a usually reversible form of left ventricular dysfunction triggered by emotional or physical stress, is another clinical manifestation of the interplay between the heart and the brain. Early recognition and management of these comorbidities in HF patients are crucial for improving outcomes. This narrative review provides an overview of the pathophysiological mechanisms linking HF and brain disorders and discusses clinical perspectives of heart-brain interactions in the context of HF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leptin and heart failure: the chicken or the egg?

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-17 DOI: 10.1007/s10741-025-10501-6

Nikolaos Theodorakis, Maria Nikolaou

{"title":"Leptin and heart failure: the chicken or the egg?","authors":"Nikolaos Theodorakis, Maria Nikolaou","doi":"10.1007/s10741-025-10501-6","DOIUrl":"https://doi.org/10.1007/s10741-025-10501-6","url":null,"abstract":"Leptin plays a dual role in heart failure (HF), acting as either a primary driver or a secondary phenomenon depending on the HF subtype. In HF with preserved ejection fraction (HFpEF), chronic hyperleptinemia is a primary mediator of disease initiation and progression, closely linked to obesity and metabolic dysfunction. Elevated leptin levels promote systemic inflammation, sympathetic nervous system activation, arterial stiffness, myocardial hypertrophy, fibrosis, and sodium retention, culminating in diastolic dysfunction and elevated ventricular filling pressures. Conversely, in HF with reduced ejection fraction (HFrEF), elevated leptin levels arise as a secondary response to myocardial dysfunction, systemic inflammation, and tissue hypoperfusion. Here, leptin exacerbates cardiac dysfunction by amplifying neurohormonal activation, inflammation, and cardiac remodeling. Understanding these distinct roles has potential therapeutic implications. In HFpEF, interventions such as weight loss, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and mineralocorticoid receptor antagonists can improve symptoms and prognosis, partly by mitigating chronic hyperleptinemia. Furthermore, leptin-specific therapies should be investigated in clinical trials as potential approach in managing cardiometabolic HFpEF. In HFrEF, management focuses on guideline-directed therapies targeting neurohormonal activation-the key mechanism driving disease progression. However, future research should explore whether modulating leptin signaling could provide additional benefits translated in hard clinical endpoints. By framing leptin as the initiator (\"chicken\") in HFpEF and a consequence (\"egg\") in HFrEF, this manuscript highlights the need for individualized, integrated treatment strategies. Addressing both metabolic and cardiovascular components could potentially further improve patient outcomes and quality of life.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF).

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-13 DOI: 10.1007/s10741-025-10504-3

Brandon Pecchia, Roy Samuel, Vacha Shah, Emily Newman, Gregory T Gibson

引用次数: 0

Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-12 DOI: 10.1007/s10741-025-10500-7

Andrew Ndakotsu, Tagbo Charles Nduka, Simran Agrawal, Edinen Asuka

{"title":"Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.","authors":"Andrew Ndakotsu, Tagbo Charles Nduka, Simran Agrawal, Edinen Asuka","doi":"10.1007/s10741-025-10500-7","DOIUrl":"https://doi.org/10.1007/s10741-025-10500-7","url":null,"abstract":"Cirrhotic cardiomyopathy (CCM) is a cardiac dysfunction linked to chronic liver disease, primarily characterized by impaired cardiac response to stress, despite normal baseline function. It presents with both systolic and diastolic dysfunction, along with electrophysiological changes such as QT interval prolongation. CCM is driven by a combination of systemic inflammation, nitric oxide-induced vasodilation, and neurohormonal dysregulation, leading to myocardial impairment and abnormal vascular responses. Clinically, CCM often remains asymptomatic at rest, but patients may experience exercise intolerance or heart failure during stress. Diagnosis includes echocardiographic evaluation, biomarker analysis (NT-proBNP, troponins), and electrocardiography for detecting electrophysiologic abnormalities. Management is complicated by cirrhosis, limiting the use of conventional heart failure treatments, with liver transplantation being the most definitive intervention in severe cases. Early detection of CCM is vital, particularly for patients undergoing liver transplantation or major surgery, where cardiac complications can increase mortality. Further research is necessary to refine diagnostic criteria and treatment strategies.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy.

IF 4.5 2区医学

Heart Failure Reviews Pub Date : 2025-03-08 DOI: 10.1007/s10741-025-10502-5

Song Peng Ang, Jia Ee Chia, Debabrata Mukherjee

{"title":"Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy.","authors":"Song Peng Ang, Jia Ee Chia, Debabrata Mukherjee","doi":"10.1007/s10741-025-10502-5","DOIUrl":"10.1007/s10741-025-10502-5","url":null,"abstract":"Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by the pathological deposition of misfolded transthyretin (TTR) protein in the myocardium, leading to restrictive cardiomyopathy and heart failure. While TTR stabilizers such as tafamidis and acoramidis are the only FDA-approved treatments, novel gene-modulating therapies are emerging as transformative approaches. Small interfering RNA (siRNA) and antisense oligonucleotide (ASO) therapies effectively reduce TTR production and have demonstrated promising clinical outcomes, though their use in cardiac amyloidosis remains investigational. CRISPR-Cas9 therapies represent a paradigm shift, offering a potential one-time treatment by permanently silencing the TTR gene. Recent clinical trials have shown significant TTR reduction and stabilization of disease biomarkers, although long-term safety and efficacy require further evaluation. Despite the lack of direct comparisons among these modalities, their emergence highlights a promising future for ATTR-CM management. This review discusses the pathogenesis of ATTR-CM, mechanisms of novel gene-modulating therapies, clinical evidence, challenges, and the future outlook for advancing treatment options.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0